omega diagnostics group plc said monday that it expects to report that its fiscal 2023 ebitda loss widened on the back of lowerthanexpected production yields and higher rawmaterial costs the medical diagnostics company said it expects to report a loss before interest taxes depreciation and amortization for the year ended march 31 of around 2 million pounds 25 million compared with previous forecast of a gbp10 million loss reported in january this compares with an ebitda loss of gbp382000 a year ago revenue however is anticipated to come in at gbp75 million below the gbp86 million reported a year ago but in line with the expected revenue range previously guided whilst its disappointing to have challenges regarding the lowerthanexpected production yields we have taken swift action to bring in consultants to oversee a number of process improvements and are confident the actions being taken will deliver a material improvement in yield in the near term chief executive jag grewal said the company said demand for food sensitivity tests continues to be robust and the order book is holding up well